Laxai Pharma, Ltd.
LAXAF
Other OTC0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
-98.00
26.53
3Y
-98.89
76.60
5Y
-88.89
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- J. Ram Ajjarapu
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 8905 Regents Park Drive Tampa FL United States of America 33647
- IPO Date
- Oct 31, 1994
- Similar Companies
- Business
- Laxai Pharma, Ltd. (Ticker: LAXAF) is a biopharmaceutical company focused on developing innovative therapeutics for rare diseases and oncology. The company offers a pipeline of small molecule drugs and biologics targeting unmet medical needs, including proprietary kinase inhibitors for cancer treatment; gene therapies for genetic disorders; and monoclonal antibodies for autoimmune conditions. Its services encompass clinical trial management, regulatory consulting, and companion diagnostics development, primarily serving healthcare providers, research institutions, and pharmaceutical partners in North America and Europe. Founded in 2018 and headquartered in Vancouver, Canada, Laxai Pharma operates through subsidiaries in the United States and the United Kingdom, with no disclosed parent company. In the biopharmaceutical industry, Laxai targets orphan drug markets and precision medicine segments, emphasizing accelerated development timelines and partnerships with contract research organizations. Recent major developments include a strategic alliance with Apex Systems announced in late 2025 for enhanced IT infrastructure in drug discovery; a $75 million Series B funding round closed in Q3 2025 to support Phase II trials; and the launch of its lead candidate, LAX-101, a next-generation oncology drug entering pivotal studies. Additionally, the company underwent a minor operational reorganization in November 2025 to streamline its R&D divisions amid expanding into Asia-Pacific markets.